Urinary Stones Linked to Testosterone Therapy
Researchers find a higher incidence of clinically diagnosed urinary stones among men receiving testosterone replacement therapy (TRT) vs matched controls not on TRT.
Researchers find a higher incidence of clinically diagnosed urinary stones among men receiving testosterone replacement therapy (TRT) vs matched controls not on TRT.
The new guidelines focus on accurate assessment and proper monitoring.
Screening and treating all healthy men older than 65 years with testosterone is discouraged.
A large study of middle-aged men found that testosterone replacement therapy is associated with a small but significant decrease in cardiovascular risk and an increased risk of obstructive sleep apnea.
Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.
Testosterone use was also more likely at sites located in the West vs the Northeast and for care received at a community-based outpatient clinic versus a medical center.
Hypogonadal testicular cancer survivors had 15 times higher odds of metabolic syndrome than their eugonadal counterparts.
Study demonstrates decreased risk of end-stage renal disease and all-cause mortality.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
Study of older hypogonadal men does not support use of TRT to improve memory, according to researchers.